Literature DB >> 26836041

Validation of immunocytochemistry as a morphomolecular technique.

Perry Maxwell1, Manuel Salto-Tellez1.   

Abstract

Immunocytochemistry (ICC) is a long-established means for clinical laboratories to investigate material for which it is difficult to obtain tissue samples. Unlike immunohistochemistry (IHC), the cells do not retain surrounding tissue environment/architecture. This can be of benefit in that fixation is often immediate and rapid, protecting the cells. Although fixation is frequently observed as the main preanalytic variable of test quality, all cytology preanalytic factors should be identified and controlled. In addition, the validation of ICC should take the same rigorous approach that other molecular pathology techniques follow. A three-step validation protocol is offered here. The end result is a comprehensive, morphomolecular approach to ICC, with an emphasis on therapeutic ICC. Cancer Cytopathol 2016;124:540-5.
© 2016 American Cancer Society. © 2015 American Cancer Society.

Entities:  

Keywords:  immunocytochemistry; molecular diagnostics; morphomolecular; test validation

Mesh:

Substances:

Year:  2016        PMID: 26836041     DOI: 10.1002/cncy.21692

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  3 in total

Review 1.  Time for change: a new training programme for morpho-molecular pathologists?

Authors:  Caroline A Young; Hayley T Morris; David A Moore; Karin A Oien; Jessica L Lee; J Louise Jones; Manuel Salto-Tellez
Journal:  J Clin Pathol       Date:  2017-11-07       Impact factor: 3.411

2.  Theranostic application of miR-429 in HER2+ breast cancer.

Authors:  Claudia Cava; Chiara Novello; Cristina Martelli; Alessia Lodico; Luisa Ottobrini; Francesca Piccotti; Marta Truffi; Fabio Corsi; Gloria Bertoli; Isabella Castiglioni
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

3.  The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH.

Authors:  Jianfeng Xu; Zhiyong Liu; Yang Liu; Guiqiang Wu; Lingyong Zeng; Jianguo Xu
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.